

Original papers

Ogilvie P. (2014) Qualitätskriterien beim Einsatz von Fillern. *Aesthet.Dermatol.*01:14-15.

Ogilvie,P. (2014) Filler auf Kollagenbasis bei Akne Narben, Kommentar *Aesthet. Dermatol.*03:17.

Ogilvie P.(2012) Qualitätskriterien beim Einsatz von Fillern zur Gesichtsaugmentation. *J.Aesthet.Chir* doi 10.1007/s/263/-012-0166-3

Moers-Carpi M, Storck R, Howell DJ, Ogilvie P, Ogilvie A.(2012) Physician and patient satisfaction after use of calcium hydroxylapatite for cheek augmentation. *Dermatol Surg.*;38 (7 Pt 2):1217-22.

Busso M, Moers-Carpi M, Storck R, Ogilvie P, Ogilvie A. Multicenter, randomized trial assessing the effectiveness and safety of calcium hydroxylapatite for hand rejuvenation.(2010) *Dermatol Surg.*;36:790–7

Ogilvie P., Moepps B., Gierschik P., Baggiolini M., Thelen M. (2004). Unusual chemokine receptor antagonism involving a Mitogen-activated protein kinase pathway. *The Journal of Immunology* 172: 6715-6722.

Ogilvie P., Paoletti S., Ugucioni M. (2003). Eotaxin-3: a CCR2 antagonist and a chemo-repellent of human monocytes. *Blood* 102: 789-794.

Ogilvie P., Hofmann U. B., Bröcker E.-B., Hamm H. (2002). Hautmanifestationen der Fanconi Anämie. *Hautarzt* 53:253-257.

Ogilvie P., Bardi G., Loetscher P., Clark-Lewis I., Baggiolini M., Ugucioni M (2001). Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. *Blood* 97:1920-1924.

Ogilvie P., Trautmann A., Dummer W., Rose C., Bröcker E.-B., Zillikens D. (2000). Pemphigoid gestationis ohne Blasenbildung. *Hautarzt* 51: 25-30.

Dummer W., Lurz C., Rickert S., Ogilvie P., Kinkelin I., Bröcker E.-B. (1999). Modell einer Sondersprechstunde für Patienten mit atopischem Ekzem. *Hautarzt* 50: 20-26.

Wagner N., Ogilvie P., Griesser H., Hamm H., Kühl J., Bröcker E.-B. (1999). Ulzerationen an der Vulva bei einem 14-jährigen Mädchen. *Akt. Der.* 25: 178-180.

Hofmann U., Ogilvie P., Müllges W., Bröcker E.-B., Hamm H. (1998). Congenital unilateral speckled blue nevi with asymmetric spinal muscular atrophy. *J Am Acad Dermatol* 39: 326-329.

Hofmann U., Ogilvie P., Hamm H., Bröcker E.-B., Rüniger T. (1997).

Schmalspektrum-UVB versus konventionelles Breitspektrum-UVB in Kombination mit Teer: ein Halbseitenvergleich bei 11 Patienten mit Psoriasis vulgaris. *Akt. Derm.* 23: 286-289.

Ogilvie P., Bröcker E.-B. (1997).

Hepatitis-C-Virusdiagnostik. Bei welchen dermatologischen Erkrankungen ist sie sinnvoll? *Akt. Dermatol.* 23: 141-144.

Ogilvie P., Schilling K., Billingsley M.L., Schmidt H.H.H.W. (1995).

Induction and variants of neuronal nitric oxide synthase type I during synaptogenesis. *FASEB J.* 9: 799-806.

Reviews

Schmidt H.H.H.W., Hofmann H., Ogilvie P., Sennefelder H., Weinberg R. (1994). Biochemistry and regulation of nitric oxide synthase. In „Nitric oxide in neuronal communication and neurotoxicity“. Japan Scientific Press: 3-18.

Schmidt H.H.H.W., Hofmann H., Ogilvie P. (1995).

Regulation and dysregulation of nitric oxide synthases type I and III. *Curr Top Microbiol Immunol* 196:75-86.

Published Abstracts

Niforos F., Acquilla R., Ogilvie P., Safa M., Signorini M., Kerson G., King C., Dhillon B. (2015) A prospective, open-label study evaluating Juvederm Volbella with Lidocaine treatment for the correction of skin depressions in the infra-orbital area. AMWC Monte Carlo meeting, 25 March 2015.

Niforos F., Signorini M., Acquilla R., Safa M., Ogilvie P., Liew S., Jones D., Kerson G., Nathan M., King C. (2014) Creation and validation of a photonumeric scale to assess volume deficiency in the infraorbital region. AMEC meeting Paris, Sept. 30 2014.

Ogilvie P., Schilling K., Billingsley M.L., Schmidt H.H.H.W. (1994).

Developmental regulation of type I NO synthase expression: enzyme polymorphism and correlation with synaptogenesis. *Naunyn Schmiedeberg's Arch Pharmacol* 349: R22.

Hofmann H., Ogilvie P., Schilling K., Billingsley M.L., Schmidt H.H.H.W. (1994).

Developmental induction and polymorphisms of neuronal type I NO synthase. 1. International conference on biochemistry and molecular biology of nitric oxide. University Press, Los Angeles California: 68.

Ogilvie P., Wesselmann U., Rott H.D., Schrank W., Bröcker E.-B., Hamm H. (1997).

Costello-Syndrome: first family observation in favor of an autosomal-dominant transmission. *Ann Derm Venerol, Supp.*1:46.

Wagner N., Ogilvie P., Griesser H., Lurz C., Hamm H., Bröcker E.-B. (1997).
Vulvar ulcerations in childhood as a diagnostic hint to langerhans cell histiocytosis. *Ann Derm Venerol, Supp.1*:153.

Ogilvie P., Trautmann A., Rose C., Bröcker E.-B. (1998).
CD30-positives Lymphom bei einer 22-jährigen Patientin unter dem klinischen Bild eines Kerion celsi. *H+G, 73*:648.

Ogilvie P., Trautmann A., Dummer W., Rose C., Bröcker E.-B., Zillikens D. (1999).
Pemphigoid gestationis: Eine Schwangerschaftsdermatose, die ohne Blasenbildung verlaufen kann. *Hautarzt, 50*: 49.

Ogilvie P., Bardi G., Loetscher P., Clark-Lewis I., Baggiolini M., Uguccioni M. (2000).
Novel functions of human eotaxin: A CCR2 antagonist and a CCR5 agonist on monocytes. *Arch Dermatol Res 292*: 86.

Ogilvie P., Bardi G., Loetscher P., Baggiolini M., Uguccioni M. (2000).
Eotaxin: A CCR2 antagonist and a CCR5 agonist on human monocytes. *J Invest Dermatol 115*: 532.

Ogilvie P., Clark-Lewis I., Bardi G., Baggiolini M., Thelen M., Uguccioni M (2001).
Eotaxin as natural chemokine receptor antagonist: A new model for chemokine receptor signaling. *Arch Dermatol Res 293*: 30.

Ogilvie P., Clark-Lewis I., Thelen M., Baggiolini M., Uguccioni M. (2001).
Eotaxin as natural chemokine receptor antagonist: a new model for chemokine receptor signaling. *Scan J Immunol 54*:67.

Ogilvie P., Baggiolini M., Thelen M., Uguccioni M. (2002).
Antagonist signaling: A raft-independent mechanism for receptor desensitization. *Arch Dermatol Res*

Ogilvie P., Moepps B., Baggiolini M., Thelen M., Uguccioni M. (2002)
Eotaxin as endogenous chemokine receptor antagonist: a new model of receptor desensitization. *Swiss Med Wkly 132 Supp.129*: S30.